Cost-effectiveness of interventions for treating anxiety disorders: A systematic review

Journal of Affective Disorders

Volumn 210, Issue , 2017, Pages 1-13

  Ophuis, Robbin H ^a,b,c   Lokkerbol, Joran ^a,d   Heemskerk, Stella C M ^e   van Balkom, Anton J L M ^f   Hiligsmann, Mickaël ^b   Evers, Silvia M A A ^a,b  

^a NETHERLANDS INSTITUTE OF MENTAL HEALTH AND ADDICTION   (Netherlands)

^b MAASTRICHT UNIVERSITY   (Netherlands)

^c ERASMUS MEDICAL CENTER   (Netherlands)

^d UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^e MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^f VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANXIOLYTIC AGENT;

ANXIETY DISORDER; COGNITIVE BEHAVIORAL THERAPY; COST EFFECTIVENESS ANALYSIS; DRUG THERAPY; HUMAN; INTERNET; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW; COGNITIVE THERAPY; COST BENEFIT ANALYSIS; ECONOMICS; META ANALYSIS; PSYCHOLOGY; PSYCHOTHERAPY;

ANTI-ANXIETY AGENTS; ANXIETY DISORDERS; COGNITIVE THERAPY; COST-BENEFIT ANALYSIS; HUMANS; PSYCHOTHERAPY;

EID: 85006511630     PISSN: 01650327     EISSN: 15732517     Source Type: Journal    
DOI: 10.1016/j.jad.2016.12.005     Document Type: Review

References (67)

1. Andersson, E., Hedman, E., Ljótsson, B., Wikström, M., Elveling, E., Lindefors, N., Andersson, G., Kaldo, V., Rück, C., Cost-effectiveness of internet-based cognitive behavior therapy for obsessive-compulsive disorder: results from a randomized controlled trial. J. Obsessive-Compuls. Relat. Disord. 4 (2015), 47–53.
2. Andersson, E., Ljótsson, B., Hedman, E., Mattson, S., Enander, J., Andersson, G., Kaldo, V., Lindefors, N., Rück, C., Cost-effectiveness of an internet-based booster program for patients with obsessive–compulsive disorder: results from a randomized controlled trial. J. Obsessive-Compuls. Relat. Disord. 4 (2015), 14–19.
3. Arnberg, F.K., Linton, S.J., Hultcrantz, M., Heintz, E., Jonsson, U., Internet-delivered psychological treatments for mood and anxiety disorders: a systematic review of their efficacy, safety, and cost-effectiveness. PLoS One, 9, 2014, e98118.
4. Bandelow, B., Reitt, M., Rover, C., Michaelis, S., Gorlich, Y., Wedekind, D., Efficacy of treatments for anxiety disorders: a meta-analysis. Int. Clin. Psychopharmacol. 30 (2015), 183–192.
5. Berger, T., Caspar, F., Richardson, R., Kneubuhler, B., Sutter, D., Andersson, G., Internet-based treatment of social phobia: a randomized controlled trial comparing unguided with two types of guided self-help. Behav. Res. Ther. 49 (2011), 158–169.
6. Bergstrom, J., Andersson, G., Ljotsson, B., Ruck, C., Andreewitch, S., Karlsson, A., Carlbring, P., Andersson, E., Lindefors, N., Internet-versus group-administered cognitive behaviour therapy for panic disorder in a psychiatric setting: a randomised trial. BMC Psychiatry, 10, 2010, 54.
7. Bodden, D.H., Dirksen, C.D., Bogels, S.M., Nauta, M.H., De Haan, E., Ringrose, J., Appelboom, C., Brinkman, A.G., Appelboom-Geerts, K.C., Costs and cost-effectiveness of family CBT versus individual CBT in clinically anxious children. Clin. Child Psychol. Psychiatry 13 (2008), 543–564.
8. Brazier, J., Is the EQ-5D fit for purpose in mental health?. Br. J. Psychiatry 197 (2010), 348–349.
9. Caro, J.J., Briggs, A.H., Siebert, U., Kuntz, K.M., Modeling good research practices–overview: a report of the ISPOR-SMDM modeling good research practices task force–1. Value Health.: J. Int. Soc. Pharm. Outcomes Res. 15 (2012), 796–803.
10. Cuijpers, P., Sijbrandij, M., Koole, S.L., Andersson, G., Beekman, A.T., Reynolds, C.F. 3rd, The efficacy of psychotherapy and pharmacotherapy in treating depressive and anxiety disorders: a meta-analysis of direct comparisons. World Psychiatry.: Off. J. World Psychiatr. Assoc. (WPA) 12 (2013), 137–148.
11. De Salas-Cansado, M., Olivares, J.M., Alvarez, E., Carrasco, J.L., Barrueta, A., Rejas, J., Pregabalin versus SSRIs and SNRIs in benzodiazepine-refractory outpatients with generalized anxiety disorder: a post hoc cost-effectiveness analysis in usual medical practice in Spain. ClinEcon. Outcomes Res.: CEOR 4 (2012), 157–168.
12. De Salas-Cansado, M., Alvarez, E., Olivares, J.M., Carrasco, J.L., Ferro, M.B., Rejas, J., Modelling the cost-effectiveness of pregabalin versus usual care in daily practice in the treatment of refractory generalised anxiety disorder in Spain. Soc. Psychiatry Psychiatr. Epidemiol. 48 (2013), 985–996.
13. Dear, B.F., Zou, J.B., Ali, S., Lorian, C.N., Johnston, L., Sheehan, J., Staples, L.G., Gandy, M., Fogliati, V.J., Klein, B., Titov, N., Clinical and cost-effectiveness of therapist-guided internet-delivered cognitive behavior therapy for older adults with symptoms of anxiety: a randomized controlled trial. Behav. Ther. 46 (2015), 206–217.
14. Donker, T., Blankers, M., Hedman, E., Ljotsson, B., Petrie, K., Christensen, H., Economic evaluations of internet interventions for mental health: a systematic review. Psychol. Med., 2015, 1–20.
15. Drummond, M.F., Sculpher, M.J., Claxton, K., Stoddart, G.L., Torrance, G.W., Methods for the Economic Evaluation of Health Care Programmes. 2015, Oxford university press, Oxford, UK.
16. Egger, N., Konnopka, A., Beutel, M.E., Herpertz, S., Hiller, W., Hoyer, J., Salzer, S., Stangier, U., Strauss, B., Willutzki, U., Wiltink, J., Leichsenring, F., Leibing, E., Konig, H.H., Short-term cost-effectiveness of psychodynamic therapy and cognitive-behavioral therapy in social anxiety disorder: results from the SOPHO-NET trial. J. Affect. Disord. 180 (2015), 21–28.
17. Eichler, H.G., Kong, S.X., Gerth, W.C., Mavros, P., Jonsson, B., Use of cost-effectiveness analysis in health-care resource allocation decision-making: how are cost-effectiveness thresholds expected to emerge?. Value Health.: J. Int. Soc. Pharm. Outcomes Res. 7 (2004), 518–528.
18. Evers, S., Goossens, M., de Vet, H., van Tulder, M., Ament, A., Criteria list for assessment of methodological quality of economic evaluations: consensus on health economic criteria. Int. J. Technol. Assess. Health care 21 (2005), 240–245.
19. Goorden, M., Muntingh, A., van Marwijk, H., Spinhoven, P., Ader, H., van Balkom, A., van der Feltz-Cornelis, C., Hakkaart-van Roijen, L., Cost utility analysis of a collaborative stepped care intervention for panic and generalized anxiety disorders in primary care. J. Psychosom. Res. 77 (2014), 57–63.
20. Gospodarevskaya, E., Segal, L., Cost-utility analysis of different treatments for post-traumatic stress disorder in sexually abused children. Child Adolesc. Psychiatry Ment. Health, 6, 2012, 15.
21. Guest, J.F., Russ, J., Lenox-Smith, A., Cost-effectiveness of venlafaxine XL compared with diazepam in the treatment of generalised anxiety disorder in the United Kingdom. Eur. J. Health Econ.: HEPAC: Health Econ. Prev. care 6 (2005), 136–145.
22. Hedman, E., Andersson, E., Ljotsson, B., Andersson, G., Ruck, C., Lindefors, N., Cost-effectiveness of Internet-based cognitive behavior therapy vs. cognitive behavioral group therapy for social anxiety disorder: results from a randomized controlled trial. Behav. Res. Ther. 49 (2011), 729–736.
23. Hedman, E., El Alaoui, S., Lindefors, N., Andersson, E., Ruck, C., Ghaderi, A., Kaldo, V., Lekander, M., Andersson, G., Ljotsson, B., Clinical effectiveness and cost-effectiveness of Internet- vs. group-based cognitive behavior therapy for social anxiety disorder: 4-year follow-up of a randomized trial. Behav. Res. Ther. 59 (2014), 20–29.
24. Heuzenroeder, L., Donnelly, M., Haby, M.M., Mihalopoulos, C., Rossell, R., Carter, R., Andrews, G., Vos, T., Cost-effectiveness of psychological and pharmacological interventions for generalized anxiety disorder and panic disorder. Aust. N.Z. J. Psychiatry 38 (2004), 602–612.
25. Higgins, J.P., Green, S., Cochrane Handbook for Systematic Reviews of Interventions. 2008, Wiley Online Library, Chichester, UK.
26. Husereau, D., Drummond, M., Petrou, S., Carswell, C., Moher, D., Greenberg, D., Augustovski, F., Briggs, A.H., Mauskopf, J., Loder, E., Consolidated health economic evaluation reporting standards (CHEERS)–explanation and elaboration: a report of the ISPOR health economic evaluation publication guidelines good reporting practices task force. Value Health.: J. Int. Soc. Pharm. Outcomes Res. 16 (2013), 231–250.
27. Iskedjian, M., Walker, J.H., Bereza, B.G., Le Melledo, J.M., Einarson, T.R., Cost-effectiveness of escitalopram for generalized anxiety disorder in Canada. Curr. Med. Res. Opin. 24 (2008), 1539–1548.
28. Issakidis, C., Sanderson, K., Corry, J., Andrews, G., Lapsley, H., Modelling the population cost-effectiveness of current and evidence-based optimal treatment for anxiety disorders. Psychol. Med. 34 (2004), 19–35.
29. Joesch, J.M., Sherbourne, C.D., Sullivan, G., Stein, M.B., Craske, M.G., Roy-Byrne, P., Incremental benefits and cost of coordinated anxiety learning and management for anxiety treatment in primary care. Psychol. Med. 42 (2012), 1937–1948.
30. Jorgensen, T.R., Stein, D.J., Despiegel, N., Drost, P.B., Hemels, M.E., Baldwin, D.S., Cost-effectiveness analysis of escitalopram compared with paroxetine in treatment of generalized anxiety disorder in the United Kingdom. Ann. Pharmacother. 40 (2006), 1752–1758.
31. Katon, W., Russo, J., Sherbourne, C., Stein, M.B., Craske, M., Fan, M.Y., Roy-Byrne, P., Incremental cost-effectiveness of a collaborative care intervention for panic disorder. Psychol. Med. 36 (2006), 353–363.
32. Katon, W.J., Roy-Byrne, P., Russo, J., Cowley, D., Cost-effectiveness and cost offset of a collaborative care intervention for primary care patients with panic disorder. Arch. Gen. Psychiatry 59 (2002), 1098–1104.
33. Kolbasovsky, A., Reich, L., Futterman, R., Meyerkopf, N., Reducing the number of emergency department visits and costs associated with anxiety: a randomized controlled study. Am. J. Manag. Care 13 (2007), 95–102.
34. Konig, H.H., Born, A., Gunther, O., Matschinger, H., Heinrich, S., Riedel-Heller, S.G., Angermeyer, M.C., Roick, C., Validity and responsiveness of the EQ-5D in assessing and valuing health status in patients with anxiety disorders. Health Qual. Life Outcomes, 8, 2010, 47.
35. Konig, H.H., Born, A., Heider, D., Matschinger, H., Heinrich, S., Riedel-Heller, S.G., Surall, D., Angermeyer, M.C., Roick, C., Cost-effectiveness of a primary care model for anxiety disorders. Br. J. Psychiatry 195 (2009), 308–317.
36. Konnopka, A., Leichsenring, F., Leibing, E., Konig, H.H., Cost-of-illness studies and cost-effectiveness analyses in anxiety disorders: a systematic review. J. Affect Disord. 114 (2009), 14–31.
37. Lambert, R.A., Lorgelly, P., Harvey, I., Poland, F., Cost-effectiveness analysis of an occupational therapy-led lifestyle approach and routine general practitioner's care for panic disorder. Soc. Psychiatry Psychiatr. Epidemiol. 45 (2010), 741–750.
38. Le, Q.A., Doctor, J.N., Zoellner, L.A., Feeny, N.C., Cost-effectiveness of prolonged exposure therapy versus pharmacotherapy and treatment choice in posttraumatic stress disorder (the optimizing PTSD treatment trial): a doubly randomized preference trial. J. Clin. Psychiatry 75 (2014), 222–230.
39. Lepine, J.P., The epidemiology of anxiety disorders: prevalence and societal costs. J. Clin. Psychiatry 63:Suppl 14 (2002), 4–8.
40. Marchand, A., Germain, V., Reinharz, D., Mainguy, N., Landry, P., Analysis of the cost and the effectiveness of a psychotherapy for panic disorder with agoraphobia (PDA) versus a treatment combining pharmacotherapy and psychotherapy. Sante Mentale au Quebec 29 (2004), 201–220.
41. Mavissakalian, M.R., Schmier, J.K., Flynn, J.A., Revicki, D.A., Cost effectiveness of acute imipramine therapy versus two imipramine maintenance treatment regimens for panic disorder. PharmacoEconomics 18 (2000), 383–391.
42. Mavranezouli, I., Meader, N., Cape, J., Kendall, T., The cost effectiveness of pharmacological treatments for generalized anxiety disorder. PharmacoEconomics 31 (2013), 317–333.
43. Mavranezouli, I., Mayo-Wilson, E., Dias, S., Kew, K., Clark, D.M., Ades, A.E., Pilling, S., The cost effectiveness of psychological and pharmacological interventions for social anxiety disorder: a model-based economic analysis. PLoS One, 10, 2015, e0140704.
44. McCrone, P., Marks, I.M., Mataix-Cols, D., Kenwright, M., McDonough, M., Computer-aided self-exposure therapy for phobia/panic disorder: a pilot economic evaluation. Cogn. Behav. Ther. 38 (2009), 91–99.
45. McHugh, R.K., Otto, M.W., Barlow, D.H., Gorman, J.M., Shear, M.K., Woods, S.W., Cost-efficacy of individual and combined treatments for panic disorder. J. Clin. Psychiatry 68 (2007), 1038–1044.
46. Mihalopoulos, C., Chen, G., Iezzi, A., Khan, M.A., Richardson, J., Assessing outcomes for cost-utility analysis in depression: comparison of five multi-attribute utility instruments with two depression-specific outcome measures. Br. J. Psychiatry 205 (2014), 390–397.
47. Mihalopoulos, C., Magnus, A., Lal, A., Dell, L., Forbes, D., Phelps, A., Is implementation of the 2013 Australian treatment guidelines for posttraumatic stress disorder cost-effective compared to current practice? A cost-utility analysis using QALYs and DALYs. Aust. N.Z. J. Psychiatry 49 (2015), 360–376.
48. Moher, D., Liberati, A., Tetzlaff, J., Altman, D.G., Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med., 6, 2009, e1000097.
49. Nordgren, L.B., Hedman, E., Etienne, J., Bodin, J., Kadowaki, A., Eriksson, S., Lindkvist, E., Andersson, G., Carlbring, P., Effectiveness and cost-effectiveness of individually tailored internet-delivered cognitive behavior therapy for anxiety disorders in a primary care population: a randomized controlled trial. Behav. Res. Ther. 59 (2014), 1–11.
50. Olesen, J., Gustavsson, A., Svensson, M., Wittchen, H.U., Jonsson, B., The economic cost of brain disorders in Europe. Eur. J. Neurol.: Off. J. Eur. Fed. Neurol. Soc. 19 (2012), 155–162.
51. Organisation for Economic Co-operation and Development (OECD), 2015a. Monthly Comparative Price Levels, (http://stats.oecd.org/Index.aspx?DataSetCode=CPL), (accessed 08.02.16).
52. Organisation for Economic Co-operation and Development (OECD), 2015b. PPP and Exchange Rates, (https://data.oecd.org/conversion/purchasing-power-parities-ppp.htm) - indicator-chart, (accessed 08.02.16).
53. Otto, M.W., Pollack, M.H., Maki, K.M., Empirically supported treatments for panic disorder: costs, benefits, and stepped care. J. Consult. Clin. Psychol. 68 (2000), 556–563.
54. Poirier-Bisson, J., Marchand, A., Pelland, M.E., Lessard, M.J., Dupuis, G., Fleet, R., Roberge, P., Incremental cost-effectiveness of pharmacotherapy and two brief cognitive-behavioral therapies compared with usual care for panic disorder and noncardiac chest pain. J. Nerv. Ment. Dis. 201 (2013), 753–759.
55. Ramsey, S., Willke, R., Briggs, A., Brown, R., Buxton, M., Chawla, A., Cook, J., Glick, H., Liljas, B., Petitti, D., Reed, S., Good research practices for cost-effectiveness analysis alongside clinical trials: the ISPOR RCT-CEA task force report. Value Health.: J. Int. Soc. Pharm. Outcomes Res. 8 (2005), 521–533.
56. Roberge, P., Marchand, A., Reinharz, D., Savard, P., Cognitive-behavioral treatment for panic disorder with agoraphobia: a randomized, controlled trial and cost-effectiveness analysis. Behav. Modif. 32 (2008), 333–351.
57. Schnurr, P.P., Friedman, M.J., Oxman, T.E., Dietrich, A.J., Smith, M.W., Shiner, B., Forshay, E., Gui, J., Thurston, V., RESPECT-PTSD: re-engineering systems for the primary care treatment of PTSD, a randomized controlled trial. J. Gen. Intern. Med. 28 (2013), 32–40.
58. Shiroiwa, T., Sung, Y.K., Fukuda, T., Lang, H.C., Bae, S.C., Tsutani, K., International survey on willingness-to-pay (WTP) for one additional QALY gained: what is the threshold of cost effectiveness?. Health Econ. 19 (2010), 422–437.
59. Silva Miguel, L., Silva Miguel, N., Ines, M., A cost-utility analysis of pregabalin versus venlafaxine XR in the treatment of generalized anxiety disorder in Portugal. Cost. Eff. Resour. Alloc.: C./E, 11, 2013, 8.
60. Slobbe, L., Kommer, G., Smit, J., Groen, J., Meerding, W., Polder, J., Kosten van ziekten in Nederland 2003. Zorg voor Eur.'S., 2006, 1.
61. Smolders, M., Laurant, M., Verhaak, P., Prins, M., van Marwijk, H., Penninx, B., Wensing, M., Grol, R., Which physician and practice characteristics are associated with adherence to evidence-based guidelines for depressive and anxiety disorders?. Med. Care 48 (2010), 240–248.
62. Titov, N., Andrews, G., Johnston, L., Schwencke, G., Choi, I., Shyness programme: longer term benefits, cost-effectiveness, and acceptability. Aust. N.Z. J. Psychiatry 43 (2009), 36–44.
63. Tolin, D.F., Diefenbach, G.J., Gilliam, C.M., Stepped care versus standard cognitive-behavioral therapy for obsessive-compulsive disorder: a preliminary study of efficacy and costs. Depress. Anxiety 28 (2011), 314–323.
64. van Apeldoorn, F.J., Stant, A.D., van Hout, W.J., Mersch, P.P., den Boer, J.A., Cost-effectiveness of CBT, SSRI, and CBT+SSRI in the treatment for panic disorder. Acta Psychiatr. Scand. 129 (2014), 286–295.
65. van Balkom, A.J.L.M., van Oppen, P., Vermeulen, A.W.A., van Dyck, R., Nauta, M.C.E., Vorst, H.C.M., A meta-analysis on the treatment of obsessive compulsive disorder: a comparison of antidepressants, behavior, and cognitive therapy. Clin. Psychol. Rev. 14 (1994), 359–381.
66. Vera-Llonch, M., Dukes, E., Rejas, J., Sofrygin, O., Mychaskiw, M., Oster, G., Cost-effectiveness of pregabalin versus venlafaxine in the treatment of generalized anxiety disorder: findings from a Spanish perspective. Eur. J. Health Econ.: HEPAC: Health Econ. Prev. care 11 (2010), 35–44.
67. Zhang, J., Xu, H., Chen, Z., Pharmacoeconomic evaluation of venlafaxine compared with citalopram in generalized anxiety disorder. Exp. Ther. Med. 5 (2013), 840–844.